Travere Therapeutics ( TVTX ) is a San Diego-based biopharmaceutical company specialized in rare kidney and metabolic diseases, with the key product FILSPARI (sparsentan) that is fully approved for IgA Nephropathy (IgAN). It was slated for a PDUFA decision on Jan 13, 2026, for focal segmental glomerulosclerosis (FSGS), butAnalyst’s Disclosure: I/we have a beneficial long position in the shares of TVTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresse ...